CN115838371A - 一种茚并吡唑类化合物的合成方法 - Google Patents
一种茚并吡唑类化合物的合成方法 Download PDFInfo
- Publication number
- CN115838371A CN115838371A CN202211720811.XA CN202211720811A CN115838371A CN 115838371 A CN115838371 A CN 115838371A CN 202211720811 A CN202211720811 A CN 202211720811A CN 115838371 A CN115838371 A CN 115838371A
- Authority
- CN
- China
- Prior art keywords
- indenopyrazole
- nmr
- cdcl
- synthesizing
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 indenopyrazole compound Chemical class 0.000 title claims abstract description 19
- 238000010189 synthetic method Methods 0.000 title claims description 3
- 238000006243 chemical reaction Methods 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 15
- XSTBCICLDQSQIQ-UHFFFAOYSA-N indeno[2,1-c]pyrazole Chemical class C1=CC=C2C3=CN=NC3=CC2=C1 XSTBCICLDQSQIQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003054 catalyst Substances 0.000 claims abstract description 11
- 239000000654 additive Substances 0.000 claims abstract description 9
- 230000000996 additive effect Effects 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 8
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052703 rhodium Inorganic materials 0.000 claims abstract description 7
- 239000010948 rhodium Substances 0.000 claims abstract description 7
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052707 ruthenium Inorganic materials 0.000 claims abstract description 7
- 125000003118 aryl group Chemical group 0.000 claims abstract description 6
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 150000002466 imines Chemical class 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 4
- 229910018286 SbF 6 Inorganic materials 0.000 claims description 4
- DEUJSGDXBNTQMY-UHFFFAOYSA-N 1,2,2-trifluoroethanol Chemical compound OC(F)C(F)F DEUJSGDXBNTQMY-UHFFFAOYSA-N 0.000 claims description 3
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical group FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 2
- BJWMSGRKJIOCNR-UHFFFAOYSA-N 4-ethenyl-1,3-dioxolan-2-one Chemical compound C=CC1COC(=O)O1 BJWMSGRKJIOCNR-UHFFFAOYSA-N 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940071536 silver acetate Drugs 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims 6
- LAXRNWSASWOFOT-UHFFFAOYSA-J (cymene)ruthenium dichloride dimer Chemical group [Cl-].[Cl-].[Cl-].[Cl-].[Ru+2].[Ru+2].CC(C)C1=CC=C(C)C=C1.CC(C)C1=CC=C(C)C=C1 LAXRNWSASWOFOT-UHFFFAOYSA-J 0.000 claims 1
- NSQGAJNAJLBBNB-UHFFFAOYSA-N [Ag].[SH2]=N.FC(F)F.FC(F)F Chemical compound [Ag].[SH2]=N.FC(F)F.FC(F)F NSQGAJNAJLBBNB-UHFFFAOYSA-N 0.000 claims 1
- 238000001308 synthesis method Methods 0.000 abstract description 6
- 125000000524 functional group Chemical group 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 229920002554 vinyl polymer Polymers 0.000 abstract description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 30
- 238000004009 13C{1H}-NMR spectroscopy Methods 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000003454 indenyl group Chemical class C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/584—Recycling of catalysts
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明公开了一种茚并吡唑类化合物的合成方法，属于有机合成技术领域。以芳基偶氮甲碱亚胺类化合物1和4‑乙烯基‑1,3‑二氧环戊‑2‑酮2为原料，在钌或铑催化剂和添加剂存在下，空气氛围下，有机溶剂中升温反应，得到茚并吡唑类化合物3。本发明通过芳基偶氮甲碱亚胺与乙烯基环状碳酸酯的串联反应，高效合成了茚并吡唑类化合物。该方法具有原料简单易得、反应条件温和、官能团相容性好、产物收率高、选择性好、原子经济性高等优点。
Description
技术领域
本发明具体涉及一种茚并吡唑类化合物的合成方法，属于有机合成技术领域。
背景技术
茚并吡唑类化合物具有多种重要的药物活性，如抑制微管蛋白聚合、抗分枝杆菌、抗精神抑郁和消炎等，在新药开发中有着十分广泛的应用。另外，该类化合物还具有独特的分子结构和丰富的反应性能，常用于制备香料、染料和植物生长调节剂等精细化学品。
茚并吡唑类化合物具有重要的研究和应用价值，然而该类化合物的合成方法仍很有限，而且这些文献方法尚存在原料昂贵、条件苛刻、官能团耐受性差等问题。
因此，研究开发从价廉易得原料出发，在温和条件下，高效构建茚并吡唑类分子骨架的新方法仍显得非常必要。
发明内容
为了克服上述存在的技术问题，本发明提供了一种茚并吡唑类化合物的合成方法。该合成方法通过芳基偶氮甲碱亚胺与乙烯基环状碳酸酯的串联反应，高效合成了茚并吡唑类化合物。该方法具有原料简单易得、反应条件温和、官能团相容性好、产物收率高、选择性好、原子经济性高等优点。
本发明所述茚并吡唑类化合物的合成方法，包括如下操作：以芳基偶氮甲碱亚胺类化合物1和4-乙烯基-1,3-二氧环戊-2-酮2为原料，在钌或铑催化剂和添加剂存在下，有机溶剂中升温反应，得到茚并吡唑类化合物3；反应方程式表示为：
其中R1为氢、C1-4烷基、C1-4烷氧基、卤素或三氟甲基，R1为一元或二元取代，R2为氢或C1-4烷基，R3为氢或C1-4烷基，R4为氢或C1-4烷基。
进一步地，在上述技术方案中，所述有机溶剂为六氟异丙醇、2,2,2-三氟乙醇或N,N-二甲基甲酰胺。
进一步地，在上述技术方案中，所述添加剂为六氟锑酸银、双三氟甲烷磺酰亚胺银盐、醋酸银或醋酸钠。
进一步地，在上述技术方案中，所述钌催化剂为二氯双(4-甲基异丙基苯基)钌(II)([Ru(p-cymene)Cl2]2)，所述铑催化剂为二(六氟锑酸)三乙腈(五甲基环戊二烯基)铑(III)([RhCp*(MeCN)3](SbF6)2)。
进一步地，在上述技术方案中，所述芳基偶氮甲碱亚胺1、4-乙烯基-1,3-二氧环戊-2-酮2、钌或铑催化剂与添加剂摩尔比为1-2:1-2:0.01-0.05:0.1-0.2。
进一步地，在上述技术方案中，所述反应温度为80-120℃。
进一步地，在上述技术方案中，所述反应在空气氛围下进行。
发明有益效果：
本发明与现有技术相比具有以下优点：(1)合成过程简单、高效，通过芳基偶氮甲碱亚胺直接与乙烯基环状碳酸酯的串联反应，即可高效合成茚并吡唑类化合物，具有原子经济性高的特点；(2)原料价廉易得；(3)操作简便；(4)底物适用范围广、官能团耐受性好。
附图说明
图1为实施例3中化合物3p的X-射线单晶衍射图。
具体实施方式
以下通过实施例对本发明的上述内容做进一步详细说明，但不应该将此理解为本发明上述主题的范围仅限于以下的实施例，凡基于本发明上述内容实现的技术均属于本发明的范围。
实施例1
向15mL反应管中依次加入化合物1a、2、催化剂、添加剂和溶剂，在空气条件下将反应管密封，并置于加热模块中升温搅拌反应。待反应结束后，冷却至室温，抽滤，滤液浓缩，过硅胶柱分离(石油醚/乙酸乙酯＝1/1)得黄色油状产物3a。
通过改变反应的溶剂、催化剂、添加剂、温度和物料比等反应条件，得到一系列的结果，见表1。
表1不同条件下3a的合成a
实施例2
向15mL反应管中依次加入1a(40.4mg,0.2mmol)、2(34.2mg,0.3mmol)、[RhCp*(MeCN)3](SbF6)2(8.3mg,0.01mmol)、AgSbF6(6.9mg,0.02mmol)和2,2,2-三氟乙醇(2mL)，然后将反应管密封，并置于120℃油浴中反应6h。反应结束后，将反应体系冷却至室温，抽滤，滤液浓缩，过硅胶柱分离(石油醚/乙酸乙酯＝1/1)得到黄色油状产物3a(44.7mg,82％)。1HNMR(600MHz,CDCl3):δ7.29-7.25(m,3H),7.22-7.21(m,1H),5.55(br s,1H),4.62(d,J＝8.4Hz,1H),3.99(d,J＝12.0Hz,1H),3.88(dd,J1＝12.0Hz,J2＝8.4Hz,1H),3.23(t,J＝9.0Hz,1H),3.10(dd,J1＝16.8Hz,J2＝7.8Hz,1H),2.85-2.79(m,3H),2.37(d,J＝15.6Hz,1H),1.50(s,3H),1.27(s,3H).13C{1H}NMR(150MHz,CDCl3):δ164.9,142.5,140.3,128.4,127.6,125.5,125.3,64.0,63.75,63.69,61.6,49.7,46.8,34.3,26.3,19.6.HRMS(ESI)m/z:[M+H]+Calcd for C16H21N2O2 273.1598；Found 273.1590.
实施例3
依照实施例2的方法和步骤a,b，通过改变反应物1，可以合成出一系列茚并吡唑类化合物3，具体结果如下：
a反应条件：1(0.2mmol),2(0.3mmol),[RhCp*(MeCN)3](SbF6)2(5mol％),六氟锑酸银(0.02mmol),2,2,2-三氟乙醇(2mL),120℃,6h,空气氛围；b分离收率。
代表性产物表征数据如下：10-(Hydroxymethyl)-3,3,7-trimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3b)
1H NMR(600MHz,CDCl3):δ7.11(d,J＝7.8Hz,1H),7.08(d,J＝7.8Hz,1H),7.06(s,1H),5.55(dd,J1＝11.4Hz,J2＝3.6Hz,1H),4.61(d,J＝8.4Hz,1H),4.03-3.99(m,1H),3.92-3.88(m,1H),3.25(t,J＝9.0Hz,1H),3.07(dd,J1＝16.2Hz,J2＝7.2Hz,1H),2.86-2.81(m,2H),2.77(d,J＝16.2Hz,1H),2.40(d,J＝15.0Hz,1H),2.36(s,3H),1.54(s,3H),1.28(s,3H).13C{1H}NMR(150MHz,CDCl3):δ165.0,140.7,138.6,128.6,126.1,125.0,64.1,63.8,61.6,49.6,47.2,34.3,26.2,21.3,19.9.HRMS(ESI)m/z:[M+H]+Calcd for C17H23N2O2287.1754；Found 287.1750.
7-(tert-Butyl)-10-(hydroxymethyl)-3,3-dimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3c)
1H NMR(600MHz,CDCl3):δ7.33(dd,J1＝8.4Hz,J2＝1.8Hz,1H),7.25(s,1H),7.20(d,J＝7.8Hz,1H),5.56(dd,J1＝11.4Hz,J2＝3.6Hz,1H),4.62(d,J＝8.4Hz,1H),4.01(td,J1＝12.6Hz,J2＝2.4Hz,1H),3.92-3.88(m,1H),3.29(t,J＝8.4Hz,1H),3.11(dd,J1＝16.2Hz,J2＝7.2Hz,1H),2.88-2.81(m,3H),2.39(d,J＝15.6Hz,1H),1.51(s,3H),1.30(s,9H),1.29(s,3H).13C{1H}NMR(150MHz,CDCl3):δ164.8,151.9,140.3,139.5,125.1,124.7,122.2,63.8,63.7,63.6,61.8,49.8,47.1,34.7,34.5,31.5,26.4,19.7.HRMS(ESI)m/z:[M+H]+Calcd for C20H29N2O2 329.2224；Found 329.2215.
10-(Hydroxymethyl)-7-methoxy-3,3-dimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3d)
1H NMR(600MHz,CDCl3):δ7.16(d,J＝8.4Hz,1H),6.83(dd,J1＝8.4Hz,J2＝2.4Hz,1H),6.74(d,J＝1.8Hz,1H),5.57(br s,1H),4.59(d,J＝8.4Hz,1H),4.00(dd,J1＝12.0Hz,J2＝2.4Hz,1H),3.89(dd,J1＝12.6Hz,J2＝8.4Hz,1H),3.79(s,3H),3.29(t,J＝9.0Hz,1H),3.09(dd,J1＝16.2Hz,J2＝7.2Hz,1H),2.87-2.78(m,3H),2.39(d,J＝15.0Hz,1H),1.50(s,3H),1.28(s,3H).13C{1H}NMR(150MHz,CDCl3):δ164.9,160.3,142.1,134.4,126.0,114.3,110.1,63.8,63.6,63.5,61.8,55.5,49.7,47.5,34.6,26.4,19.8.HRMS(ESI)m/z:[M+H]+Calcd for C17H23N2O3 303.1703；Found 303.1704.
7-Fluoro-10-(hydroxymethyl)-3,3-dimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3e)
1H NMR(400MHz,CDCl3):δ7.21(dd,J1＝8.0Hz,J2＝5.2Hz,1H),6.98(td,J1＝8.8Hz,J2＝2.0Hz,1H),6.91(d,J＝8.8Hz,1H),5.47(dd,J1＝10.8Hz,J2＝3.6Hz,1H),4.60(d,J＝8.0Hz,1H),4.05-3.98(m,1H),3.92-3.86(m,1H),3.27(t,J＝8.8Hz,1H),3.12(dd,J1＝16.4Hz,J2＝7.2Hz,1H),2.92-2.88(m,1H),2.85-2.79(m,2H),2.39(d,J＝15.2Hz,1H),1.50(s,3H),1.28(s,3H).13C{1H}NMR(100MHz,CDCl3):δ165.0,163.3(d,1JC-F＝244.1Hz),142.6(d,3JC-F＝8.7Hz),138.1(d,4JC-F＝2.9Hz),126.6(d,3JC-F＝9.4Hz),115.0(d,2JC-F＝23.1Hz),112.2(d,2JC-F＝22.4Hz),63.8,63.7,63.3,61.5,49.6,47.3,34.3(d,4JC-F＝2.1Hz),26.3,19.7.19F NMR(565MHz,CDCl3):δ-114.30--114.34(m).HRMS(ESI)m/z:[M+H]+Calcd for C16H20FN2O2 291.1503；Found 291.1503.
7-Chloro-10-(hydroxymethyl)-3,3-dimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3f)
1H NMR(600MHz,CDCl3):δ7.25(dd,J1＝8.4Hz,J2＝1.8Hz,1H),7.21(s,1H),7.18(d,J＝7.8Hz,1H),5.47-5.45(m,1H),4.59(d,J＝7.8Hz,1H),4.01(t,J＝10.2Hz,1H),3.88(dd,J1＝12.6Hz,J2＝8.4Hz,1H),3.24(t,J＝9.0Hz,1H),3.10(dd,J1＝16.2Hz,J2＝7.2Hz,1H),2.87(dd,J1＝15.6Hz,J2＝7.8Hz,1H),2.83-2.78(m,2H),2.39(d,J＝15.6Hz,1H),1.49(s,3H),1.28(s,3H).13C{1H}NMR(150MHz,CDCl3):δ165.0,142.3,141.1,134.3,128.0,126.5,125.6,63.7,63.6,63.4,61.5,49.6,47.0,34.1,26.3,19.7.HRMS(ESI)m/z:[M+H]+Calcd for C16H20ClN2O2 307.1208；Found 307.1204.
7-Bromo-10-(hydroxymethyl)-3,3-dimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3g)
1H NMR(600MHz,CDCl3):δ7.40(d,J＝7.8Hz,1H),7.38(s,1H),7.13(d,J＝7.8Hz,1H),5.44(dd,J1＝10.8Hz,J2＝3.6Hz,1H),4.57(d,J＝8.4Hz,1H),4.03-3.99(m,1H),3.90-3.86(m,1H),3.24(t,J＝9.0Hz,1H),3.12(dd,J1＝16.8Hz,J2＝7.2Hz,1H),2.88-2.79(m,3H),2.39(d,J＝15.0Hz,1H),1.49(s,3H),1.28(s,3H).13C{1H}NMR(150MHz,DMSO-d6):δ164.5,144.9,142.9,130.2,128.5,128.0,121.4,63.3,63.0,62.3,60.0,49.8,48.7,35.0,26.3,19.7.HRMS(ESI)m/z:[M+Na]+Calcd for C16H19BrN2NaO2 373.0522；Found 373.0512.
10-(Hydroxymethyl)-3,3-dimethyl-7-(trifluoromethyl)-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3h)
1H NMR(600MHz,CDCl3):δ7.55(d,J＝7.8Hz,1H),7.50(s,1H),7.38(d,J＝7.8Hz,1H),5.38-5.37(m,1H),4.67(d,J＝8.4Hz,1H),4.04(t,J＝10.8Hz,1H),3.92-3.89(m,1H),3.23(t,J＝9.0Hz,1H),3.18(dd,J1＝16.2Hz,J2＝7.2Hz,1H),2.93(dd,J1＝16.2Hz,J2＝8.4Hz,1H),2.88(d,J＝16.8Hz,1H),2.84(d,J＝15.6Hz,1H),2.41(d,J＝15.6Hz,1H),1.53(s,3H),1.30(s,3H).13C{1H}NMR(150MHz,CDCl3):165.0,146.5,141.1,131.0(q,2JC-F＝32.9Hz),125.9,124.9(q,3JC-F＝4.4Hz),124.1(q,1JC-F＝271.4Hz),122.5(q,3JC-F＝4.4Hz),63.9,63.8,63.5,61.3,49.5,46.8,34.1,26.4,19.7.19F NMR(565MHz,CDCl3):δ-62.24(s).HRMS(ESI)m/z:[M+H]+Calcd for C17H20F3N2O2 341.1471；Found 341.1467.
10-(Hydroxymethyl)-3,3,6-trimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3i)
1H NMR(600MHz,CDCl3):δ7.15(d,J＝7.8Hz,1H),7.09(d,J＝8.4Hz,1H),7.04(s,1H),5.60(dd,J1＝10.8Hz,J2＝3.6Hz,1H),4.60(d,J＝8.4Hz,1H),4.02-3.98(m,1H),3.91-3.87(m,1H),3.28(t,J＝9.0Hz,1H),3.08(dd,J1＝16.2Hz,J2＝7.2Hz,1H),2.86-2.82(m,2H),2.78(d,J＝16.8Hz,1H),2.39(d,J＝15.0Hz,1H),2.34(s,3H),1.51(s,3H),1.28(s,3H).13C{1H}NMR(150MHz,CDCl3):δ165.0,142.5,137.5,137.2,129.5,125.7,125.3,64.0,63.9,63.8,61.6,49.6,47.0,33.8,26.3,21.4,19.7.HRMS(ESI)m/z:[M+H]+Calcd forC17H23N2O2 287.1754；Found 287.1749.
6-Chloro-10-(hydroxymethyl)-3,3-dimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3j)
1H NMR(400MHz,CDCl3):δ7.25-7.22(m,2H),7.15(d,J＝8.0Hz,1H),5.42(dd,J1＝10.8Hz,J2＝4.0Hz,1H),4.61(d,J＝8.4Hz,1H),4.05-3.99(m,1H),3.92-3.86(m,1H),3.23(t,J＝9.2Hz,1H),3.08(dd,J1＝16.4Hz,J2＝7.2Hz,1H),2.90-2.82(m,2H),2.78(d,J＝16.8Hz,1H),2.39(d,J＝15.2Hz,1H),1.52(s,3H),1.27(s,3H).13C{1H}NMR(150MHz,CDCl3):δ165.1,144.6,138.6,133.4,128.8,126.6,125.6,63.9,63.8,63.7,61.4,49.6,47.0,33.7,26.3,19.6.HRMS(ESI)m/z:[M+H]+Calcd for C16H20ClN2O2 307.1208；Found307.1206.
6-Bromo-10-(hydroxymethyl)-3,3-dimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3k)
1H NMR(600MHz,CDCl3):δ7.38(dd,J1＝8.4Hz,J2＝1.8Hz,1H),7.37(s,1H),7.10(d,J＝7.8Hz,1H),5.42(dd,J1＝10.8Hz,J2＝3.6Hz,1H),4.62(d,J＝8.4Hz,1H),4.04-3.00(m,1H),3.91-3.87(m,1H),3.23(t,J＝9.0Hz,1H),3.06(dd,J1＝16.8Hz,J2＝7.2Hz,1H),2.87-2.82(m,2H),2.76(d,J＝16.8Hz,1H),2.39(d,J＝15.6Hz,1H),1.52(s,3H),1.27(s,3H).13C{1H}NMR(150MHz,CDCl3):δ165.1,145.0,139.2,131.6,128.6,127.0,121.4,63.9,63.8,63.7,61.4,49.5,46.9,33.7,26.4,19.6.HRMS(ESI)m/z:[M+H]+Calcd forC16H20BrN2O2 351.0703；Found 351.0701.10-(Hydroxymethyl)-6-methoxy-3,3-dimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3l)
1H NMR(600MHz,CDCl3):δ7.13(d,J＝7.8Hz,1H),6.83(dd,J1＝8.4Hz,J2＝1.8Hz,1H),6.78(d,J＝1.8Hz,1H),5.52-5.50(m,1H),4.60(d,J＝7.8Hz,1H),4.01(t,J＝10.8Hz,1H),3.91-3.88(m,1H),3.81(s,3H),3.26(t,J＝9.6Hz,1H),3.05(dd,J1＝15.6Hz,J2＝7.2Hz,1H),2.86-2.82(m,2H),2.74(d,J＝16.2Hz,1H),2.39(d,J＝15.0Hz,1H),1.52(s,3H),1.28(s,3H).13C{1H}NMR(150MHz,CDCl3):δ164.9,159.7,144.0,132.1,126.2,114.7,110.3,64.1,63.8,63.7,61.7,55.5,49.7,47.3,33.4,26.4,19.6.HRMS(ESI)m/z:[M+H]+Calcd for C17H23N2O3 303.1703；Found 303.1696.
10-(Hydroxymethyl)-8-methoxy-3,3-dimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3m)
1H NMR(600MHz,CDCl3):δ7.28-7.26(m,1H),6.87(d,J＝7.2Hz,1H),6.76(d,J＝7.8Hz,1H),5.50(br s,1H),4.64(d,J＝8.4Hz,1H),4.03-4.01(m,1H),3.89(dd,J1＝12.6Hz,J2＝8.4Hz,1H),3.83(s,3H),3.26(t,J＝9.0Hz,1H),2.97(dd,J1＝16.2Hz,J2＝6.6Hz,1H),2.88-2.82(m,3H),2.39(d,J＝15.0Hz,1H),1.51(s,3H),1.28(s,3H).13C{1H}NMR(150MHz,CDCl3):δ164.9,156.5,144.3,129.4,128.3,117.1,109.4,64.5,63.9,63.7,61.6,55.3,49.7,46.7,31.1,26.4,19.6.HRMS(ESI)m/z:[M+H]+Calcd for C17H23N2O3303.1703；Found 303.1702.
6-Fluoro-10-(hydroxymethyl)-3,3-dimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3n)
1H NMR(600MHz,CDCl3):δ7.17(dd,J1＝7.8Hz,J2＝4.8Hz,1H),6.98-6.94(m,2H),5.44(dd,J1＝10.8Hz,J2＝3.6Hz,1H),4.61(d,J＝8.4Hz,1H),4.04-4.00(m,1H),3.92-3.88(m,1H),3.25(t,J＝9.0Hz,1H),3.08(dd,J1＝15.6Hz,J2＝7.2Hz,1H),2.90-2.83(m,2H),2.77(d,J＝16.2Hz,1H),2.40(d,J＝15.6Hz,1H),1.51(s,3H),1.28(s,3H).13C{1H}NMR(150MHz,CDCl3):δ165.0,162.8(d,1JC-F＝243.9Hz),144.8(d,3JC-F＝7.7Hz),135.5(d,4JC-F＝2.3Hz),126.6(d,3JC-F＝7.7Hz),115.8(d,2JC-F＝23.0Hz),112.2(d,2JC-F＝23.0Hz),63.9,63.8,63.7,61.5,49.6,47.3,33.5,26.3,19.6.19F NMR(565MHz,CDCl3):δ-115.2--115.3(m).HRMS(ESI)m/z:[M+H]+Calcd for C16H20FN2O2 291.1503；Found 291.1500.
8-Fluoro-10-(hydroxymethyl)-3,3-dimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3o)
1H NMR(600MHz,CDCl3):δ7.29-7.27(m,1H),7.06(d,J＝7.8Hz,1H),6.96(t,J＝9.0Hz,1H),5.42(dd,J1＝10.8Hz,J2＝3.6Hz,1H),4.66(d,J＝7.8Hz,1H),4.06-4.02(m,1H),3.92-3.88(m,1H),3.26(t,J＝8.4Hz,1H),3.08(dd,J1＝16.8Hz,J2＝7.2Hz,1H),2.93-2.90(m,2H),2.83(d,J＝15.6Hz,1H),2.40(d,J＝15.6Hz,1H),1.51(s,3H),1.29(s,3H).13C{1H}NMR(150MHz,CDCl3):δ165.0,159.7(d,1JC-F＝247.2Hz),146.1(d,3JC-F＝5.6Hz),129.8(d,3JC-F＝7.8Hz),126.8(d,2JC-F＝17.6Hz),120.9(d,4JC-F＝3.3Hz),114.7(d,2JC-F＝20.7Hz),64.2(d,4JC-F＝2.1Hz),63.8,63.6,61.4,49.6,46.8,30.3,26.4,19.7.19F NMR(565MHz,CDCl3):δ-117.50--117.53(m).HRMS(ESI)m/z:[M+H]+Calcd for C16H20FN2O2291.1503；Found291.1504.
10-(Hydroxymethyl)-3,3,5-trimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3p)
1H NMR(400MHz,CDCl3):δ7.15(t,J＝7.6Hz,1H),7.04(d,J＝7.2Hz,1H),7.00(d,J＝7.6Hz,1H),5.30(dd,J1＝10.4Hz,J2＝3.6Hz,1H),4.70(d,J＝7.2Hz,1H),4.08-4.01(m,1H),3.96-3.90(m,1H),3.22(t,J＝8.8Hz,1H),3.01(dd,J1＝16.0Hz,J2＝6.8Hz,1H),2.84(d,J＝15.2Hz,1H),2.78-2.74(m,2H),2.48(s,3H),2.27(d,J＝14.8Hz,1H),1.52(s,3H),1.25(s,3H).13C{1H}NMR(100MHz,CDCl3):δ167.1,140.6,139.6,136.1,129.4,128.7,123.2,66.8,65.2,64.3,61.6,49.5,46.7,33.5,26.5,19.9,19.3.HRMS(ESI)m/z:[M+H]+Calcd for C17H23N2O2 287.1754；Found287.1746.
5-Fluoro-10-(hydroxymethyl)-3,3-dimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3q)
1H NMR(400MHz,CDCl3):δ7.28-7.23(m,1H),7.01(d,J＝7.2Hz,1H),6.92(t,J＝8.4Hz,1H),5.49(br s,1H),4.80(d,J＝8.0Hz,1H),4.01(dd,J1＝12.4Hz,J2＝2.4Hz,1H),3.90(dd,J1＝12.4Hz,J2＝8.0Hz,1H),3.39(t,J＝8.4Hz,1H),3.12(dd,J1＝16.8Hz,J2＝8.0Hz,1H),2.95-2.89(m,2H),2.86(d,J＝16.0Hz,1H),2.39(d,J＝15.2Hz,1H),1.47(d,J＝2.0Hz,3H),1.32(s,3H).13C{1H}NMR(150MHz,CDCl3):δ164.9,160.1(d,1JC-F＝248.3Hz),144.6(d,3JC-F＝5.4Hz),130.8(d,3JC-F＝7.8Hz),128.4(d,2JC-F＝14.3Hz),121.2(d,4JC-F＝3.3Hz),114.3(d,2JC-F＝20.7Hz),64.4,63.2,62.1(d,4JC-F＝2.3Hz),62.0,50.0,47.9,35.1,25.8(d,3JC-F＝5.4Hz),19.6.19F NMR(565MHz,CDCl3):δ-116.08--116.11(m).HRMS(ESI)m/z:[M+H]+Calcd for C16H20FN2O2 291.1503；Found 291.1502.
10-(Hydroxymethyl)-3,3,6,7-tetramethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3r)
1H NMR(600MHz,CDCl3):δ7.01(s,1H),7.00(s,1H),5.56(dd,J1＝10.8Hz,J2＝3.0Hz,1H),4.59(d,J＝8.4Hz,1H),4.02-3.98(m,1H),3.91-3.87(m,1H),3.25(t,J＝9.0Hz,1H),3.05(dd,J1＝16.2Hz,J2＝7.2Hz,1H),2.84-2.81(m,2H),2.74(d,J＝16.2Hz,1H),2.39(d,J＝15.6Hz,1H),2.26(s,3H),2.24(s,3H),1.53(s,3H),1.28(s,3H).13C{1H}NMR(150MHz,CDCl3):δ164.9,140.0,137.8,137.1,136.2,126.4,126.0,63.91,63.89,63.7,61.8,49.7,47.1,34.0,26.4,19.94,19.88,19.7.HRMS(ESI)m/z:[M+H]+Calcd forC18H25N2O2 301.1911；Found 301.1903.
7-Fluoro-10-(hydroxymethyl)-3,3,6-trimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3s)
1H NMR(600MHz,CDCl3):δ7.04(d,J＝7.2Hz,1H),6.86(d,J＝9.6Hz,1H),5.46(dd,J1＝10.8Hz,J2＝3.0Hz,1H),4.58(d,J＝7.8Hz,1H),4.03-3.99(m,1H),3.91-3.87(m,1H),3.25(t,J＝9.0Hz,1H),3.07(dd,J1＝16.2Hz,J2＝7.2Hz,1H),2.88-2.83(m,2H),2.76(d,J＝16.2Hz,1H),2.39(d,J＝15.0Hz,1H),2.27(s,3H),1.52(s,3H),1.28(s,3H).13C{1H}NMR(150MHz,CDCl3):δ165.0,161.7(d,1JC-F＝243.9Hz),139.5(d,3JC-F＝8.7Hz),137.8(d,4JC-F＝2.3Hz),127.7(d,3JC-F＝5.4Hz),124.6(d,2JC-F＝18.5Hz),111.8(d,2JC-F＝23.1Hz),63.81,63.78,63.5,61.5,49.6,47.3,34.0(d,4JC-F＝2.3Hz),26.4,19.7,14.8(d,3JC-F＝4.4Hz).19F NMR(565MHz,CDCl3):δ-117.93--117.96(m).HRMS(ESI)m/z:[M+H]+CalcdforC17H22FN2O2 305.1660；Found 305.1655.
10-(Hydroxymethyl)-3-methyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3t)
1H NMR(600MHz,CDCl3):δ7.32-7.30(m,1H),7.29-7.27(m,2H),7.25-7.23(m,1H),5.43-5.41(m,1H),4.34(d,J＝8.4Hz,1H),4.04-4.00(m,1H),3.93-3.90(m,1H),3.46-3.41(m,1H),3.39-3.35(m,1H),3.15(dd,J1＝16.2Hz,J2＝7.8Hz,1H),3.06-3.01(m,1H),2.89(dd,J1＝16.8Hz,J2＝2.4Hz,1H),2.74(dd,J1＝15.6Hz,J2＝7.2Hz,1H),2.65-2.60(m,1H),1.50(d,J＝6.0Hz,3H).13C{1H}NMR(150MHz,CDCl3):164.8,141.3,141.2,128.8,127.6,125.6,125.4,73.4,64.3,63.2,61.6,46.8,43.2,34.8,18.7.HRMS(ESI)m/z:[M+H]+Calcdfor C15H19N2O2 259.1441；Found259.1437.
10-(Hydroxymethyl)-3-propyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3u)
1H NMR(600MHz,CDCl3):δ7.31-7.28(m,3H),7.24-7.23(m,1H),5.38(dd,J1＝10.2Hz,J2＝3.6Hz,1H),4.36(d,J＝9.0Hz,1H),4.05-4.01(m,1H),3.93-3.89(m,1H),3.37-3.32(m,2H),3.14(dd,J1＝16.2Hz,J2＝7.8Hz,1H),3.04-3.00(m,1H),2.87(d,J＝16.2Hz,1H),2.73(dd,J1＝16.2Hz,J2＝7.2Hz,1H),2.63-2.58(m,1H),1.96-1.90(m,1H),1.76-1.70(m,1H),1.49-1.37(m,2H),1.03(t,J＝7.2Hz,3H).13C{1H}NMR(150MHz,CDCl3):δ165.0,141.4,141.2,128.8,127.6,125.6,125.4,73.5,67.6,64.1,61.5,46.6,41.0,35.7,34.6,19.2,14.2.HRMS(ESI)m/z:[M+H]+Calcd for C17H23N2O2 287.1754；Found 287.1753.
10-(Hydroxymethyl)-2,3-dimethyl-2,3,4a,9,9a,10-hexahydro-1H-indeno[1,2-c]pyrazolo[1,2-a]pyrazol-1-one(3v)
1H NMR(600MHz,CDCl3):δ7.33-7.32(m,1H),7.29-7.28(m,2H),7.25-7.23(m,1H),5.47(dd,J1＝10.8Hz,J2＝4.2Hz,1H),4.32(d,J＝8.4Hz,1H),4.05-4.01(m,1H),3.91-3.87(m,1H),3.38(t,J＝8.4Hz,1H),3.15(dd,J1＝16.8Hz,J2＝8.4Hz,1H),3.04-3.00(m,1H),2.93-2.88(m,2H),2.60-2.57(m,1H),1.50(d,J＝6.0Hz,3H),1.22(d,J＝6.6Hz,3H).13C{1H}NMR(150MHz,CDCl3):δ167.1,141.3,141.2,128.8,127.6,125.6,125.5,73.3,70.6,64.2,61.6,47.8,46.6,34.7,17.3,12.1.HRMS(ESI)m/z:[M+H]+Calcd for C16H21N2O2273.1598；Found 273.1589.
实施例4
本发明所合成的产物茚并吡唑类化合物3a可以进行一系列反应，从而合成进一步的衍生物。例如：
在50mL两颈瓶中，加入3a(54.4mg,0.2mmol)和甲苯(10mL)，氩气条件下向所得溶液中加入碘(103mg,0.4mmol)、三苯基膦(157mg,0.6mmol)和咪唑(40mg,0.6mmol)，然后将体系在110℃反应6小时。待反应结束并冷却至室温后，减压浓缩。残留物过硅胶柱分离(石油醚/乙酸乙酯＝1/1)，得到白色固体产物4(62.8mg,82％)。1H NMR(600MHz,CDCl3):δ7.28-7.25(m,2H),7.23-7.21(m,2H),4.60(d,J＝7.8Hz,1H),3.89(dd,J1＝10.2Hz,J2＝6.6Hz,1H),3.82(dd,J1＝10.8Hz,J2＝3.0Hz,1H),3.49-3.48(m,1H),3.31-3.29(m,1H),3.22(dd,J1＝16.2Hz,J2＝8.4Hz,1H),3.10(dd,J1＝15.6Hz,J2＝6.0Hz,1H),2.72(d,J＝16.2Hz,1H),2.39(d,J＝15.6Hz,1H),1.48(s,3H),1.34(s,3H).13C{1H}NMR(150MHz,CDCl3):δ163.7,142.5,141.0,128.6,127.1,125.5,125.3,62.9,61.4,57.7,55.6,50.8,36.7,26.9,20.9,7.0.
向15mL反应管中依次加入3a(54.4mg,0.2mmol)、DCC(41.3mg,0.2mmol)、DMAP(4.9mg,0.04mmol)、奥沙普秦(58.7mg,0.2mmol)和DCM(1mL)，随后将体系在室温下反应24小时。反应结束后，通过硅藻土过滤，滤液减压浓缩，过硅胶柱分离(石油醚/乙酸乙酯＝1/1)，得到白色固体产物5(77.8mg,71％)。1H NMR(600MHz,CDCl3):δ7.57(d,J＝6.6Hz,2H),7.54(d,J＝7.2Hz,2H),7.33-7.26(m,6H),7.23-7.21(m,3H),7.15(d,J＝5.4Hz,1H),4.88(dd,J1＝11.4Hz,J2＝4.2Hz,1H),4.72(dd,J1＝11.4Hz,J2＝3.0Hz,1H),4.42(d,J＝7.8Hz,1H),3.49-3.48(m,1H),3.26-3.16(m,3H),3.03-2.94(m,3H),2.88(dd,J1＝16.2Hz,J2＝3.6Hz,1H),2.74(d,J＝15.6Hz,1H),2.31(d,J＝15.0Hz,1H),1.37(s,3H),1.32(s,3H).13C{1H}NMR(150MHz,CDCl3):δ171.7,164.3,161.7,145.5,142.0,141.3,135.2,132.5,128.9,128.7,128.55,128.51,128.4,128.1,127.9,127.3,126.4,125.4,63.5,62.6,60.6,57.9,50.4,49.2,35.4,31.0,26.5,23.4,19.9.
以上实施例描述了本发明的基本原理、主要特征及优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明原理的范围下，本发明还会有各种变化和改进，这些变化和改进均落入本发明保护的范围内。
Claims (7)
1.一种茚并吡唑类化合物的合成方法，其特征在于，包括如下操作：以芳基偶氮甲碱亚胺类化合物1和4-乙烯基-1,3-二氧环戊-2-酮2为原料，在钌或铑催化剂和添加剂存在下，有机溶剂中升温反应，得到茚并吡唑类化合物3；反应方程式表示为：
其中R1为氢、C1-4烷基、C1-4烷氧基、卤素或三氟甲基，R1为一元或二元取代，R2为氢或C1-4烷基，R3为氢或C1-4烷基，R4为氢或C1-4烷基。
2.根据权利要求1所述茚并吡唑类化合物的合成方法，其特征在于：所述有机溶剂为六氟异丙醇、2,2,2-三氟乙醇或N,N-二甲基甲酰胺。
3.根据权利要求1所述茚并吡唑类化合物的合成方法，其特征在于：所述添加剂为六氟锑酸银、双三氟甲烷磺酰亚胺银盐、醋酸银或醋酸钠。
4.根据权利要求1所述茚并吡唑类化合物的合成方法，其特征在于：所述钌催化剂为[Ru(p-cymene)Cl2]2，所述铑催化剂为[RhCp*(MeCN)3](SbF6)2。
5.根据权利要求1所述茚并吡唑类化合物的合成方法，其特征在于：所述芳基偶氮甲碱亚胺1、4-乙烯基-1,3-二氧环戊-2-酮2、钌或铑催化剂与添加剂摩尔比为1-2:1-2:0.01-0.05:0.1-0.2。
6.根据权利要求1所述茚并吡唑类化合物的合成方法，其特征在于：反应温度为80-120℃。
7.根据权利要求1-6任意一项所述茚并吡唑类化合物的合成方法，其特征在于：反应在空气氛围下进行。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211720811.XA CN115838371A (zh) | 2022-12-30 | 2022-12-30 | 一种茚并吡唑类化合物的合成方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211720811.XA CN115838371A (zh) | 2022-12-30 | 2022-12-30 | 一种茚并吡唑类化合物的合成方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115838371A true CN115838371A (zh) | 2023-03-24 |
Family
ID=85577653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211720811.XA Pending CN115838371A (zh) | 2022-12-30 | 2022-12-30 | 一种茚并吡唑类化合物的合成方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115838371A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102207333B1 (ko) * | 2019-09-09 | 2021-01-27 | 성균관대학교산학협력단 | 4중 연속 고리 화합물의 신규한 제조방법 |
| CN115215814A (zh) * | 2022-09-06 | 2022-10-21 | 河南师范大学 | 异恶唑烷类化合物的合成方法 |
-
2022
- 2022-12-30 CN CN202211720811.XA patent/CN115838371A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102207333B1 (ko) * | 2019-09-09 | 2021-01-27 | 성균관대학교산학협력단 | 4중 연속 고리 화합물의 신규한 제조방법 |
| CN115215814A (zh) * | 2022-09-06 | 2022-10-21 | 河南师范大学 | 异恶唑烷类化合物的合成方法 |
Non-Patent Citations (3)
| Title |
|---|
| HEEYOUNG LEE等: "Allylic Acetals as Acrolein Oxonium Precursors in Tandem C@H Allylation and [3+2] Dipolar Cycloaddition", ANGEW. CHEM. INT. ED., pages 9470 - 9474 * |
| MAN ZHU,: "Regio- and stereo-selective construction of cis-indeno[1, 2-c]isoxazoles via a C–H allylation/1, 3-dipolar cycloaddition cascade", ORG. CHEM. FRONT., pages 5879 - 5884 * |
| WU, MIN等: "Enantioselective synthesis of indenopyrazolopyrazolones enabled by dual directing groups-assisted and rhodium(III)-catalyzed tandem C-H alkenylation/[3 + 2] stepwise cycloaddition", CHINESE CHEMICAL LETTERS, pages 842 - 846 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112898192B (zh) | 一种n-酰基吲哚化合物的制备方法 | |
| CN112441875B (zh) | 一种铜光催化合成9-三氟甲基-9,10-二氢菲类化合物的方法 | |
| JPH0776209B2 (ja) | 光学活性３―ヒドロキシピロリジン誘導体の製造方法 | |
| CN110372708B (zh) | 一种5H-苯并[c]咪唑并[1,2-a]氮杂环庚烯-6-羧酸类化合物的合成方法 | |
| CN109879788B (zh) | 一种制备n-取代吲哚衍生物的方法 | |
| CN115838371A (zh) | 一种茚并吡唑类化合物的合成方法 | |
| CN115785096B (zh) | 高选择性合成吡唑啉酮螺二氢喹啉或吡唑啉酮螺吲哚啉类化合物的方法 | |
| CN114409688B (zh) | 一种2-硼化苯并噻唑衍生物的合成方法 | |
| US4222970A (en) | Process for producing phosphonomycin | |
| JP6733449B2 (ja) | ベルベリン型アルカロイドの製造方法 | |
| CN109761947B (zh) | 一种官能化苯并色烯类化合物的合成方法 | |
| CN113214256A (zh) | 1,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁基酯的合成方法 | |
| JPS5980685A (ja) | Ｎ−低級アルカノイルグアニン誘導体およびそれを用いる方法 | |
| CN111393258B (zh) | 一种合成四氢萘-2-醇衍生物类化合物的方法 | |
| CN113735867B (zh) | 一种手性吲哚并氧杂七元环化合物及其合成方法 | |
| CN108299445B (zh) | 一种1,5-氮杂螺[2,4]庚烷的合成方法 | |
| CN110092802B (zh) | 一种制备曲贝替定中间体的方法 | |
| RU2818458C2 (ru) | Способы и промежуточные соединения для получения ингибитора btk | |
| CN112441874B (zh) | 一种铱光催化合成9-三氟甲基-9,10-二氢菲类化合物的方法 | |
| CN109912521B (zh) | 一种一步合成烯基取代的1,2,3-三氮唑衍生物的方法 | |
| WO2023007712A1 (ja) | （ｒ，ｓ）－ニコチンの製造方法 | |
| JP2767287B2 (ja) | インドール類の製造法 | |
| KR101525296B1 (ko) | 라미부딘 옥살레이트 및 이의 제조방법 | |
| JP2680683B2 (ja) | ソラネシルアミン誘導体の製造方法 | |
| CN116768904A (zh) | 一种手性四氢吲哚并咔唑化合物及其合成方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |